ATRA (Atara Biotherapeutics) Other Long-Term Liabilities: $42.39 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ATRA Atara Biotherapeutics Inc ATRA
20 GF Score
Price $8.36
GF Value $0.39
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Atara Biotherapeutics Other Long-Term Liabilities?

Atara Biotherapeutics ATRA +3.34% 20 Other Long-Term Liabilities is $42.39 Mil as of Jun. 2026. GuruFocus rates ATRA with a GF Score™ of 20/100 and a GF Value™ of $0.39 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Atara Biotherapeutics's other long-term liabilities for the quarter that ended in Jun. 2026 was $42.39 Mil.

Atara Biotherapeutics's quarterly other long-term liabilities increased from Dec. 2025 ($34.47 Mil) to Mar. 2026 ($42.59 Mil) but then declined from Mar. 2026 ($42.59 Mil) to Jun. 2026 ($42.39 Mil).

Atara Biotherapeutics's annual other long-term liabilities increased from Dec. 2023 ($39.25 Mil) to Dec. 2024 ($41.89 Mil) but then declined from Dec. 2024 ($41.89 Mil) to Dec. 2025 ($34.47 Mil).

Atara Biotherapeutics Other Long-Term Liabilities Related Terms

Atara Biotherapeutics Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Atara Biotherapeutics's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atara Biotherapeutics Other Long-Term Liabilities Chart

Atara Biotherapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.50 35.80 39.25 41.89 34.47

Atara Biotherapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 41.95 33.74 34.47 42.59 42.39
ATRA
20GF Score
Atara Biotherapeutics Inc ATRA
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Atara Biotherapeutics Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of $42.39 Mil mean?
Atara Biotherapeutics (ATRA) has a Other Long-Term Liabilities of $42.39 Mil as of Jun. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Atara Biotherapeutics and its competitors.
Is Atara Biotherapeutics' Other Long-Term Liabilities too high?
Atara Biotherapeutics' current Other Long-Term Liabilities is $42.39 Mil. Overall, Atara Biotherapeutics has a GF Score™ of 20/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Atara Biotherapeutics' Other Long-Term Liabilities compare to IBIO and ANVS?
Atara Biotherapeutics' Other Long-Term Liabilities of $42.39 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Biotechnology company?
A good Other Long-Term Liabilities depends on the Biotechnology industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Atara Biotherapeutics and its competitors. Atara Biotherapeutics's current Other Long-Term Liabilities is $42.39 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atara Biotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Atara Biotherapeutics (ATRA) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.39, compared to a current price of $8.36 — trading 2043.6% above its estimated fair value. The current Other Long-Term Liabilities is $42.39 Mil. Atara Biotherapeutics' overall GF Score™ is 20/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Atara Biotherapeutics (ATRA), the current Other Long-Term Liabilities is $42.39 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Atara Biotherapeutics (ATRA) Overvalued in 2026?

Based on GuruFocus' analysis, Atara Biotherapeutics stock appears to be overvalued. The current stock price of $8.36 is trading 2043.6% above its estimated GF Value™ of $0.39. GuruFocus considers Atara Biotherapeutics to be Significantly Overvalued.

Key valuation signals for ATRA:

  • Other Long-Term Liabilities: $42.39 Mil
  • GF Value™: $0.39 vs. price of $8.36 (2043.6% above fair value)
  • GF Score™: 20/100 with 5 warning signs

No single metric tells the full story. See the ATRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Atara Biotherapeutics Business Description

Other Exchanges 0HIY:UKAT20:Germany
Address 1280 Rancho Conejo Boulevard, Suite 200, Thousand Oaks, CA, USA, 91320
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.
20GF Score

Get the complete analysis for ATRA

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.36
Price
$0.39
GF Value